ACE2 News and Research

RSS

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

20 Oct 2023

Low serotonin levels observed in long COVID and other viral infections

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

20 Oct 2023

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

The efficacy of tea and its catechins in deactivating the Omicron subvariant.

5 Oct 2023

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

The power of nanobodies: How they impact COVID-19 immune response

The structures of 340 antibodies (Abs) and 83 nanobodies.

25 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA's multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

14 Sep 2023

Eris sublineage EG.5.1 can escape neutralizing antibodies better than other SARS-CoV-2 lineages

As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells.

14 Sep 2023

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers identify a new SARS-CoV-2 variant, BA.2.86, with enhanced ability to evade immunity but lower infectivity compared to current variants. The study highlights the need for global monitoring due to its potential to become a predominant strain if it gains infectivity through mutations.

6 Sep 2023

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.

6 Sep 2023

Can SARS-CoV-2 infect poultry?

New research in the Virology Journal suggests that chickens could become intermediate hosts for newly emerged SARS-CoV-2 variants, posing a potential threat to public health. The study identifies AXL and ACE2 receptors in chickens as likely binding sites for the virus, highlighting the need for further research and preventive measures.

5 Sep 2023

SARS-CoV-2 Eris variant spreads faster and dodges immunity

Study investigates the characteristics of the EG.5.1 "Eris" variant of SARS-CoV-2, finding it more transmissible among hamsters and slightly better at evading immunity compared to the XBB.1.5 variant. The results suggest that these properties could be driving the variant's increasing prevalence in human populations.

5 Sep 2023

Study characterizes SARS-CoV-2 subvariants to inform development of next-generation COVID-19 vaccines

Researchers characterized two novel SARS-CoV-2 XBB variants, EG.5.1 and XBB.2.3.

4 Sep 2023

Study investigates the pathophysiological mechanisms of PASC after COVID-19

Researchers investigated early pathophysiological mechanisms potentially underlying PASC post-SARS-CoV-2 infection.

4 Sep 2023

Engineered ACE2 decoy shows promise as COVID-19 treatment

Researchers from Japan demonstrated that an engineered angiotensin-converting enzyme 2 (ACE2) receptor, which showed the potential to remarkably reduce the emergence of resistant virus strains, could successfully exert its therapeutic effect in primates, which may open avenues for the application of the technology for the treatment of humans.

30 Aug 2023

Unlocking ACE2: The enzyme that links COVID-19, heart disease, and diabetes

A recent study in the Journal of Biomedical Science examines the critical role of ACE2, an enzyme involved in blood volume and electrolyte balance, in chronic diseases like cardiovascular conditions, diabetes, and COVID-19. The research suggests that ACE2 could serve as both a disease severity biomarker and a therapeutic target.

28 Aug 2023

ACE2 News and Research

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

Low serotonin levels observed in long COVID and other viral infections

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

The power of nanobodies: How they impact COVID-19 immune response

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Eris sublineage EG.5.1 can escape neutralizing antibodies better than other SARS-CoV-2 lineages

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Can SARS-CoV-2 infect poultry?

SARS-CoV-2 Eris variant spreads faster and dodges immunity

Study characterizes SARS-CoV-2 subvariants to inform development of next-generation COVID-19 vaccines

Study investigates the pathophysiological mechanisms of PASC after COVID-19

Engineered ACE2 decoy shows promise as COVID-19 treatment

Unlocking ACE2: The enzyme that links COVID-19, heart disease, and diabetes

Differences in immune responses to IL-6 inhibition therapy between male and female COVID-19 patients

How does COVID-19 influence your gut microbiota?

A hybrid approach to re-engineer a SARS-CoV-1 neutralizing antibody against SARS-CoV-2

Proxalutamide shows promise as potential COVID-19 treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News